Cover Image
市場調查報告書

Simcere Pharmaceutical Group - 產品平台分析

Simcere Pharmaceutical Group - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224591
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
Simcere Pharmaceutical Group - 產品平台分析 Simcere Pharmaceutical Group - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 53 Pages
簡介

Simcere Pharmaceutical Group (Simcere) 開發、提供抗癌劑、心臟血管治療藥、腦血管治療藥、抗菌劑、抗病毒劑、抗骨骼疏鬆症等有效藥物。

本報告提供Simcere Pharmaceutical Group的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Simcere Pharmaceutical Group的基本資料

Simcere Pharmaceutical Group概要

  • 主要資訊
  • 企業資料

Simcere Pharmaceutical Group:R&D概要

  • 主要的治療範圍

Simcere Pharmaceutical Group:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Simcere Pharmaceutical Group:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • ND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床階段的產品/聯合治療模式
  • ■Simcere Pharmaceutical Group:藥物簡介
  • bendamustine hydrochloride
  • Recombinant Human Endostatin + cisplatin + vinorelbine tartrate
  • fluorouracil
  • (irbesartan + amlodipine)
  • APX-003
  • SIM-071201
  • Simotinib Hydrochloride
  • BMS-817378
  • OSI-930
  • SIM-010603
  • SIM-0710
  • BMS-795311
  • SIM-89

Simcere Pharmaceutical Group:開發平台分析

  • 各治療分類
  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Simcere Pharmaceutical Group:最近的開發平台趨勢

Simcere Pharmaceutical Group:暫停中的計劃

Simcere Pharmaceutical Group:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07976CDB

Summary

Global Markets Direct's, 'Simcere Pharmaceutical Group - Product Pipeline Review - 2016', provides an overview of the Simcere Pharmaceutical Group's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Simcere Pharmaceutical Group, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Simcere Pharmaceutical Group
  • The report provides overview of Simcere Pharmaceutical Group including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Simcere Pharmaceutical Group's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Simcere Pharmaceutical Group's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Simcere Pharmaceutical Group's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Simcere Pharmaceutical Group
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Simcere Pharmaceutical Group's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Simcere Pharmaceutical Group Snapshot
    • Simcere Pharmaceutical Group Overview
    • Key Information
    • Key Facts
  • Simcere Pharmaceutical Group - Research and Development Overview
    • Key Therapeutic Areas
  • Simcere Pharmaceutical Group - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Simcere Pharmaceutical Group - Pipeline Products Glance
    • Simcere Pharmaceutical Group - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Simcere Pharmaceutical Group - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Simcere Pharmaceutical Group - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Simcere Pharmaceutical Group - Drug Profiles
    • SIM-071201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bendamustine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (amlodipine besylate + irbesartan)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APX-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • metatinib tromethamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • abatacept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-817378
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OSI-930
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SIM-010603
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SIM-0710
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-795311
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SCR-1693
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SIM-89
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Simcere Pharmaceutical Group - Pipeline Analysis
    • Simcere Pharmaceutical Group - Pipeline Products by Target
    • Simcere Pharmaceutical Group - Pipeline Products by Route of Administration
    • Simcere Pharmaceutical Group - Pipeline Products by Molecule Type
    • Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action
  • Simcere Pharmaceutical Group - Recent Pipeline Updates
  • Simcere Pharmaceutical Group - Dormant Projects
  • Simcere Pharmaceutical Group - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Simcere Pharmaceutical Group, Key Information
  • Simcere Pharmaceutical Group, Key Facts
  • Simcere Pharmaceutical Group - Pipeline by Indication, 2016
  • Simcere Pharmaceutical Group - Pipeline by Stage of Development, 2016
  • Simcere Pharmaceutical Group - Monotherapy Products in Pipeline, 2016
  • Simcere Pharmaceutical Group - Combination Treatment Modalities in Pipeline, 2016
  • Simcere Pharmaceutical Group - Partnered Products in Pipeline, 2016
  • Simcere Pharmaceutical Group - Partnered Products/ Combination Treatment Modalities, 2016
  • Simcere Pharmaceutical Group - Phase III, 2016
  • Simcere Pharmaceutical Group - Phase II, 2016
  • Simcere Pharmaceutical Group - Phase I, 2016
  • Simcere Pharmaceutical Group - IND/CTA Filed, 2016
  • Simcere Pharmaceutical Group - Preclinical, 2016
  • Simcere Pharmaceutical Group - Discovery, 2016
  • Simcere Pharmaceutical Group - Pipeline by Target, 2016
  • Simcere Pharmaceutical Group - Pipeline by Route of Administration, 2016
  • Simcere Pharmaceutical Group - Pipeline by Molecule Type, 2016
  • Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action, 2016
  • Simcere Pharmaceutical Group - Recent Pipeline Updates, 2016
  • Simcere Pharmaceutical Group - Dormant Developmental Projects,2016
  • Simcere Pharmaceutical Group, Subsidiaries

List of Figures

  • Simcere Pharmaceutical Group - Pipeline by Top 10 Indication, 2016
  • Simcere Pharmaceutical Group - Pipeline by Stage of Development, 2016
  • Simcere Pharmaceutical Group - Monotherapy Products in Pipeline, 2016
  • Simcere Pharmaceutical Group - Partnered Products in Pipeline, 2016
  • Simcere Pharmaceutical Group - Pipeline by Top 10 Target, 2016
  • Simcere Pharmaceutical Group - Pipeline by Route of Administration, 2016
  • Simcere Pharmaceutical Group - Pipeline by Molecule Type, 2016
  • Simcere Pharmaceutical Group - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top